<?xml version='1.0' encoding='utf-8'?>
<document id="31835322"><sentence text="Doxycycline and Monocaprin In Situ Hydrogel: Effect on Stability, Mucoadhesion and Texture Analysis and In Vitro Release."><entity charOffset="0-11" id="DDI-PubMed.31835322.s1.e0" text="Doxycycline" /><entity charOffset="16-26" id="DDI-PubMed.31835322.s1.e1" text="Monocaprin" /><pair ddi="false" e1="DDI-PubMed.31835322.s1.e0" e2="DDI-PubMed.31835322.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31835322.s1.e0" e2="DDI-PubMed.31835322.s1.e1" /></sentence><sentence text="The aim of this study was to develop a stable aqueous formulation containing a combination of doxycycline and monocaprin in clinically relevant concentrations"><entity charOffset="94-105" id="DDI-PubMed.31835322.s2.e0" text="doxycycline" /><entity charOffset="110-120" id="DDI-PubMed.31835322.s2.e1" text="monocaprin" /><pair ddi="false" e1="DDI-PubMed.31835322.s2.e0" e2="DDI-PubMed.31835322.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31835322.s2.e0" e2="DDI-PubMed.31835322.s2.e1" /></sentence><sentence text=" Increase in expression of Matrix metalloproteinases (MMPs) and microbial role in oral diseases is well established and the combination of above active ingredients could be potentially beneficial in treatment of oral mucosal conditions" /><sentence text=" The hydrogels containing different concentrations of doxycycline and monocaprin in the presence and absence of stabilizing excipients were developed and their stabilities were studied at 4 °C for up to 1 year"><entity charOffset="54-65" id="DDI-PubMed.31835322.s4.e0" text="doxycycline" /><entity charOffset="70-80" id="DDI-PubMed.31835322.s4.e1" text="monocaprin" /><pair ddi="false" e1="DDI-PubMed.31835322.s4.e0" e2="DDI-PubMed.31835322.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31835322.s4.e0" e2="DDI-PubMed.31835322.s4.e1" /></sentence><sentence text=" The drug-drug interaction was evaluated using Fourier-transform infrared spectroscopy (FTIR)" /><sentence text=" The addition of monocaprin on doxycycline in situ hydrogel's mucoadhesiveness, texture properties and drug release mechanism was studied"><entity charOffset="17-27" id="DDI-PubMed.31835322.s6.e0" text="monocaprin" /><entity charOffset="31-42" id="DDI-PubMed.31835322.s6.e1" text="doxycycline" /><pair ddi="false" e1="DDI-PubMed.31835322.s6.e0" e2="DDI-PubMed.31835322.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31835322.s6.e0" e2="DDI-PubMed.31835322.s6.e1" /></sentence><sentence text=" The addition of monocaprin negatively affected the doxycycline stability and was concentration dependent, whereas monocaprin was stable up to 1 year"><entity charOffset="17-27" id="DDI-PubMed.31835322.s7.e0" text="monocaprin" /><entity charOffset="52-63" id="DDI-PubMed.31835322.s7.e1" text="doxycycline" /><entity charOffset="115-125" id="DDI-PubMed.31835322.s7.e2" text="monocaprin" /><pair ddi="false" e1="DDI-PubMed.31835322.s7.e0" e2="DDI-PubMed.31835322.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31835322.s7.e0" e2="DDI-PubMed.31835322.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31835322.s7.e0" e2="DDI-PubMed.31835322.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31835322.s7.e1" e2="DDI-PubMed.31835322.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31835322.s7.e1" e2="DDI-PubMed.31835322.s7.e2" /></sentence><sentence text=" Doxycycline did not interfere with the anti-Candidal activity of monocaprin"><entity charOffset="1-12" id="DDI-PubMed.31835322.s8.e0" text="Doxycycline" /><entity charOffset="66-76" id="DDI-PubMed.31835322.s8.e1" text="monocaprin" /><pair ddi="false" e1="DDI-PubMed.31835322.s8.e0" e2="DDI-PubMed.31835322.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31835322.s8.e0" e2="DDI-PubMed.31835322.s8.e1" /></sentence><sentence text=" Furthermore, the presence of monocaprin significantly affected the formulation hardness, compressibility and adhesiveness"><entity charOffset="30-40" id="DDI-PubMed.31835322.s9.e0" text="monocaprin" /></sentence><sentence text=" Monocaprin and doxycycline release followed zero order kinetics and the release mechanism was, by anomalous (non-Fickian) diffusion"><entity charOffset="1-11" id="DDI-PubMed.31835322.s10.e0" text="Monocaprin" /><entity charOffset="16-27" id="DDI-PubMed.31835322.s10.e1" text="doxycycline" /><pair ddi="false" e1="DDI-PubMed.31835322.s10.e0" e2="DDI-PubMed.31835322.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31835322.s10.e0" e2="DDI-PubMed.31835322.s10.e1" /></sentence><sentence text=" The addition of monocaprin increased the drug release time and altered the release mechanism"><entity charOffset="17-27" id="DDI-PubMed.31835322.s11.e0" text="monocaprin" /></sentence><sentence text=" It is possible to stabilize doxycycline in the presence of monocaprin up to 1 year at 4 °C"><entity charOffset="29-40" id="DDI-PubMed.31835322.s12.e0" text="doxycycline" /><entity charOffset="60-70" id="DDI-PubMed.31835322.s12.e1" text="monocaprin" /><pair ddi="false" e1="DDI-PubMed.31835322.s12.e0" e2="DDI-PubMed.31835322.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31835322.s12.e0" e2="DDI-PubMed.31835322.s12.e1" /></sentence><sentence text="" /></document>